Trial reportAmerican journal of hematology2017
Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Trial report in American journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04750707 (Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda), which is not on this map. Cited by 39 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hydroxyurea Therapy for Neurological and Cognitive Protection in Pediatric Sickle Cell Anemia in Uganda: A Single Arm Open Label Trial, "BRAIN SAFE II"
Who cites it
39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Global burden of moyamoya syndrome in pediatric sickle cell disease and implications for the neurosurgical workforce: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- Pooled it
- A systematic review and meta-analysis of the prevalence and predictors of anemia among children in Ethiopia.African health sciences · 2020Pooled it
- Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.The Cochrane database of systematic reviews · 2020Pooled it
- Feasibility trial for the management of severe acute malnutrition in older children with sickle cell anemia in Nigeria.Blood advances · 2023Trial
- Translating research to usual care of children with sickle cell disease in Northern Nigeria: lessons learned from the SPRING Trial Team.BMC research notes · 2022Trial
- PRIMARY STROKE PREVENTION IN CHILDREN WITH SICKLE CELL ANEMIA LIVING IN AFRICA: THE FALSE CHOICE BETWEEN PATIENT-ORIENTED RESEARCH AND HUMANITARIAN SERVICE-PART II.Transactions of the American Clinical and Climatological Association · 2022Trial
- Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial.The Lancet. Haematology · 2022Trial
- Capacity Building for Primary Stroke Prevention Teams in Children Living With Sickle Cell Anemia in Africa.Pediatric neurology · 2021Trial
- Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial.American journal of hematology · 2020Trial
- Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial.Pediatric neurology · 2019Trial
- Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations.Blood advances · 2026Article
- Hydroxyurea - Pragmatic Reduction In Mortality and Economic burden (H-PRIME): A 2x2x2 factorial randomised open-label trial investigating practical approaches to the treatment of sickle cell disease at four sites in Eastern Uganda.Wellcome open research · 2025Article
- Longitudinal assessment of transcranial Doppler imaging in children with sickle cell disease without neurological symptoms.BMC pediatrics · 2024Article
- Gut Microbiota: Potential Therapeutic Target for Sickle Cell Disease Pain and Complications.Anemia · 2024Review
- Sickle cell anemia and early stroke detection and prevention in Nigeria.Frontiers in stroke · 2024Review
- Prevention of stroke and cognitive decline in pediatric population in resource-limited settings.Frontiers in stroke · 2024Review
- Self-Reported Medication Adherence Measured with Morisky Scales in Rare Disease Patients: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2023Review
- Repeat transcranial Doppler ultrasound imaging in Kuwaiti children with sickle cell disease after a 10-year interval: A prospective, cohort study.Health science reports · 2023Article
- A Critical Review of Sickle Cell Disease Burden and Challenges in Sub-Saharan Africa.Journal of blood medicine · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
19 authors at 9 institutions in 4 countries.
Funding
Abstract
The vast majority of children with sickle cell anemia (SCA) live in Africa, where evidence-based guidelines for primary stroke prevention are lacking. In Kano, Nigeria, we conducted a feasibility trial to determine the acceptability of hydroxyurea therapy for primary stroke prevention in children with abnormal transcranial Doppler (TCD) measurements. Children with SCA and abnormal non-imaging TCD measurements (≥200 cm/s) received moderate fixed-dose hydroxyurea therapy (∼20 mg/kg/day). A comparison group of children with TCD measurements <200 cm/s was followed prospectively. Approximately 88% (330 of 375) of families agreed to be screened, while 87% (29 of 33) of those with abnormal TCD measurements, enrolled in the trial. No participant elected to withdraw from the trial. The average mean corpuscular volume increased from 85.7 fl at baseline to 95.5 fl at 24 months (not all of the children who crossed over had a 24 month visit), demonstrating adherence to hydroxyurea. The comparison group consisted of initially 210 children, of which four developed abnormal TCD measurements, and were started on hydroxyurea. None of the monthly research visits were missed (n = total 603 visits). Two and 10 deaths occurred in the treatment and comparison groups, with mortality rates of 2.69 and 1.81 per 100 patient-years, respectively (P = .67). Our results provide strong evidence, for high family recruitment, retention, and adherence rates, to undertake the first randomized controlled trial with hydroxyurea therapy for primary stroke prevention in children with SCA living in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.